

ALLERGY PRESCRIPTION FORM

Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy. Prescribers are reminded patients may choose any pharmacy of their choice.

Owl Specialty Pharmacy
 1010 E. Arrow Hwy., Covina, CA 91724
 Phone: 626-209-8169 Fax: 626-209-8171 or 855-817-9523
www.owlspecialty.com



Patient Information: please provide a copy of the patient's insurance card or information				
Patient name:		DOB:	Gender: <input type="checkbox"/> F <input type="checkbox"/> M	HT:
Address:		City:	State:	Zip Code:
Insurance:		Subscriber's name:	ID#:	Group #:
Allergies: <input type="checkbox"/> NKDA <input type="checkbox"/> List allergies:				
Clinical Information: please fax or email relevant clinical notes, labs, tests and previous medical history to expedite prior authorization				
Diagnosis / ICD-10:		IVIG indication required for administration: <input type="checkbox"/> Idiopathic Thrombocytopenic Purpura <input type="checkbox"/> Primary Immunodeficiency Syndrome <input type="checkbox"/> Chronic Inflammatory Demyelinating Polyneuropathy <input type="checkbox"/> Other (specify):		
Vital Signs: <input type="checkbox"/> Monitor BP q15min for the first hr of initial infusion, then q30-60min for the remainder of IVIG infusion <input type="checkbox"/> Monitor BP q30-60min for subsequent IVIG infusions				
Notify Physician if any of the following are observed: <input type="checkbox"/> SBP is less than 90 mmHg or greater than 180 mmHg <input type="checkbox"/> DBP is less than 50 mmHg or greater than 90 mmHg <input type="checkbox"/> Temperature is greater than 101.5 degrees F <input type="checkbox"/> Heart Rate is less than 50 or greater than 120 <input type="checkbox"/> RR is less than 10 or greater than 30 respirations/min <input type="checkbox"/> Urine Output is less than 30 mL/hr or 240 mL/shift <input type="checkbox"/> Pulse Oximetry is less than 90% <input type="checkbox"/> SBP is less than 90 mmHg or greater than 180 mmHg				
Blood Test: CBC, Metabolic Panel (chem-7) daily, prior to each infusion, Immunofixation, Immunoglobulins quantitation (Before 1st/ _____ treatment, fax results to pharmacy)				
Ig Treatment				
Decrease IVIG rate or stop infusion and notify physician if patient experiences adverse reactions: hypotension, chest tightness, fever, chills, or nausea/vomiting		Pre-Medication: <input type="checkbox"/> Acetaminophen 650 mg po one time 30-60 min prior to each dose of IVIG <input type="checkbox"/> Diphenhydramine 25 mg po one time prn 30-60 min prior to each dose of IVIG <input type="checkbox"/> Other:		
Immune Globulin: <input type="checkbox"/> Predisposed to renal insufficiency, minimize rate of infusion <input type="checkbox"/> Patient has not been treated previously with IVIG, initiate at a lower concentration or lower rate				
Pharmacist will round down to nearest vial and maintain at least 90% of calculated dose. If dose deviates by more than 10% of calculated dose, Pharmacist may round up to nearest vial. <input type="checkbox"/> Patient has been previously treated with IVIG and tolerated therapy <input type="checkbox"/> Patient has NOT been previously treated with IVIG <input type="checkbox"/> Pharmacist to use current weight for dose calculations <input type="checkbox"/> Use (specify): _____ kg as dosing weight <input type="checkbox"/> Immune globulin 0.4 g/kg IV daily Initiate first dose at 15 to 30 mL/hr and increase rate every 30-60 minutes for duration of the infusion. For subsequent doses, titrate every 15 to 30 minutes to a final maximum rate listed in infusion table.				
RX: IVIG _____ Grams _____ Days Infusion Rate: _____ cc/hr for the 1st hr _____ cc/hr for the second hr _____ cc/hr thereafter				
Repeat/Maintenance treatment in: _____ or every _____ / month				
Dose: _____ Frequency: _____ Start Date: _____ Duration: _____				
Hypersensitivity Anaphylaxis Management				
Vital Signs: <input type="checkbox"/> Vital signs every 2 minutes until stable. Then, every 5 minutes for 30 minutes, then every 15 minutes until hypersensitivity/anaphylaxis reaction subsides.		Assessments: <input type="checkbox"/> Stop the administration of any agent causing hypersensitivity/anaphylaxis reaction immediately. <input type="checkbox"/> Remain with patient, maintain airway and perform CPR if necessary.		Interventions: <input type="checkbox"/> Lay patient supine with legs elevated IMMEDIATELY <input type="checkbox"/> Oxygen therapy at 8-10 LPM via face mask
<input type="checkbox"/> Albuterol nebulization 2.5mg/3.0mL once for hypersensitivity/anaphylaxis reaction	<input type="checkbox"/> Glucagon 1 mg IV if on Beta Blockers once PRN, if patient on beta blockers and fails to respond to initial treatment	<input type="checkbox"/> Sodium chloride 0.9% bolus and infusion <input type="checkbox"/> Sodium chloride (NORMAL SALINE) 0.9 % bolus 1,000 mL, 1,000 mL, IV, once, for 30 min.		
<input type="checkbox"/> Epinephrine 1:1000 (1mg/mL) injection 0.3 mg, Intramuscular, once PRN for hypersensitivity/anaphylaxis reaction. May repeat every 5-10 minutes x 3 doses. If not effective, then may give epinephrine 0.5 mg IM. Epinephrine should be administered first, as soon as the diagnosis of anaphylaxis is suspected.	<input type="checkbox"/> Epinephrine 1:1000 (1mg/mL) injection 0.5 mg, Intramuscular, once PRN for severe cases of hypersensitivity/anaphylaxis reaction. May repeat every 5-10 minutes Epinephrine should be administered first as soon as the diagnosis of anaphylaxis is suspected.			
<input type="checkbox"/> Epinephrine 1:1000 (1mg/mL) injection 0.01 mg/kg Intramuscular, once PRN for patients who weigh less than 30 kg for hypersensitivity/anaphylaxis reaction. May repeat every 5-10 minutes Epinephrine should be administered first as soon as the diagnosis of anaphylaxis is suspected.	<input type="checkbox"/> Diphenhydramine injection 50 mg IV push once PRN over 1-2 minutes for hypersensitivity/anaphylaxis reaction (25 mg/min maximum).			
<input type="checkbox"/> Loratadine 10 mg PO once for hypersensitivity/anaphylaxis reaction	<input type="checkbox"/> Methylprednisolone injection 125 mg IV once for hypersensitivity/anaphylaxis reaction			
<input type="checkbox"/> Prednisone 60 mg PO once for hypersensitivity/anaphylaxis reaction	<input type="checkbox"/> Hydrocortisone injection 100 mg IV over 30-60 seconds once PRN for hypersensitivity/anaphylaxis reaction			
<input type="checkbox"/> Famotidine 20 mg PO once PRN for hypersensitivity/anaphylaxis reaction	<input type="checkbox"/> Famotidine 20 mg IV push over 2 minutes once PRN for hypersensitivity/anaphylaxis reaction			
Non-Ig MEDICATIONS				
Medication	Dose / Strength	Directions	Quantity	Refills
<input type="checkbox"/> Cinqair®	<input type="checkbox"/> 100 mg / 10 mL vial	<input type="checkbox"/> _____ mg IV every 4 weeks		
<input type="checkbox"/> Dupixent® atopic dermatitis	<input type="checkbox"/> Pen or <input type="checkbox"/> Syringe <input type="checkbox"/> 100 mg <input type="checkbox"/> 200 mg <input type="checkbox"/> 300 mg	<input type="checkbox"/> Loading dose - 2 injections SC on day 1 in two different injection sites <input type="checkbox"/> Maintenance dose - 1 injection SC every other week		
<input type="checkbox"/> Fasenra®	<input type="checkbox"/> 30 mg/mL Autoinjector	<input type="checkbox"/> 30 mg SC once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter		
<input type="checkbox"/> Nucala®	<input type="checkbox"/> 100 mg/mL Autoinjector	<input type="checkbox"/> 100mg SC every 4 weeks		
<input type="checkbox"/> Xolair®	<input type="checkbox"/> 75 mg/mL Prefilled syringe <input type="checkbox"/> 150 mg/mL Prefilled syringe <input type="checkbox"/> 150 mg/mL vial	<input type="checkbox"/> _____ mg SC every 2 weeks <input type="checkbox"/> _____ mg SC every 4 weeks		
Notes				
Prescriber Information				
Prescriber name:		Phone:	Office contact name:	
Prescriber address:		City:	State:	Zip:
NPI:	DEA:	Fax and/or Email:		
Prescriber signature:		Date:	<input type="checkbox"/> DO NOT SUBSTITUTE	

Important Notice: This facsimile transmission is intended to be delivered only to the named recipient(s), and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named recipient, immediately notify the sender at the address and phone number set forth herein and obtain instructions as to properly dispose of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except authority of the sender to the named addressee.